The European Randomized Study of Screening for Prostate Cancer (ERSPC) also demonstrated that population-based screening of men aged 55-75 years can reduce prostate cancer mortality [6, 7] Although population-based screening has not been embraced at the moment, individual patient testing or annual PSA testing is supported. Here, KLK3 is linked to prostate cancer.